- Home
- HTH vs KOD Comparison
HTH vs KOD Comparison
Compare HTH & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTH | KOD |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HTH | KOD |
|---|---|---|
| Price | $35.80 | $40.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $37.50 | $35.43 |
| AVG Volume (30 Days) | 300.6K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 51.72 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $152,188,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | N/A |
| P/E Ratio | $13.63 | ★ N/A |
| Revenue Growth | ★ 15.52 | N/A |
| 52 Week Low | $27.35 | $1.92 |
| 52 Week High | $40.41 | $45.60 |
Technical Indicators
Market Signals| Indicator | HTH | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 67.32 |
| Support Level | $33.79 | $21.82 |
| Resistance Level | $37.30 | N/A |
| Average True Range (ATR) | 0.67 | 3.46 |
| MACD | 0.15 | 1.95 |
| Stochastic Oscillator | 79.56 | 78.74 |
Price Performance
Historical ComparisonAbout HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The company has three segments: The banking segment includes the operations of the Bank; The broker-dealer segment includes the operations of Securities Holdings,; and the mortgage origination segment is composed of PrimeLending. Majority of revenue is from Broker-dealer Segment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.